Endocrinology Advisor Contributing Writer

Investigators examined 6 biomarkers for predicting adverse cardiovascular outcomes in patients with type 2 diabetes.

Liraglutide may reduce the incidence of myocardial infarction in patients who have a high cardiovascular risk with type 2 diabetes.